Abcellera Biologics is trading 5.07% up now at $6.22, supported by pipeline optimism despite weaker-than-expected second-quarter results.
- On August 5, 2026, revenue was $4.1 million, below expectations, while net loss widened to $55.4 million.
- The earnings call highlighted imminent ABCL635 menopause-trial data, new T-cell-engager collaborations, and at least 36 months of cash runway.
- Biotech-sector momentum, including the reported Argenx–Forte deal, appears to be supporting the advance.